A BST RACT : Background: Levodopa-carbidopa intestinal gel (designated as carbidopa-levodopa enteral suspension in the United States) provides stable plasma levodopa concentrations and reduces motor fluctuations in advanced Parkinson's disease patients through continuous delivery of levodopa via percutaneous endoscopic gastrojejunostomy. We report long-term safety and efficacy outcomes from an open-label phase 3 treatment program. Methods: PD patients (n 5 262) who completed a 12-week double-blind study and its 52-week open-label extension or a separate 54-week open-label study were enrolled in this ongoing phase 3 open-label, multinational study (NCT00660673). Safety and efficacy assessments were collected every 6 months. Results: Mean total duration of exposure to levodopacarbidopa intestinal gel was 4.1 years (range, 1.2 to 6.9 years). The overall discontinuation rate was 34% (average annual discontinuation rate, 10%). Although most patients (94%) reported an adverse event, the rate of adverse events decreased over time; 53% experienced a serious adverse event. Of patients in this extension study, 54% required jejunal tube replacement during the study, and 37% required percutaneous endoscopic gastrostomy tube replacement. Most patients were on levodopa monotherapy. Patients maintained reductions in "off" time and increases in mean "on" time without dyskinesia from initial levodopa-carbidopa intestinal gel infusion to he study end point (P < 0.001; n 5 81). Previous improvements in activities of daily living and quality of life were not maintained over the course of the study. Conclusions: This long-term study demonstrates sustained and clinically meaningful benefits from levodopacarbidopa intestinal gel in advanced PD patients.
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Although adverse event rates decreased over time, vigilance is required for device-related complications and adverse events. V C 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society K e y W ord s: Parkinson's disease; levodopa-carbidopa intestinal gel; percutaneous endoscopic gastrojejunostomy; safety; infusion As Parkinson's disease (PD) progresses, nearly 90% of patients report disabling motor complications after 9 years of levodopa treatment, 1 including fluctuations between adequate treatment ("on" time) and poor mobility ("off" time).
2 These complications may be attributed to unstable levodopa plasma concentrations because of its short half-life, a narrowing therapeutic window, and erratic gastric emptying. [2] [3] [4] To overcome irregular levodopa concentrations after oral administration, levodopa-carbidopa intestinal gel (LCIG), designated in the United States as carbidopa-levodopa enteral suspension, continuously delivers levodopa via percutaneous endoscopic gastrojejunostomy (PEG-J). LCIG is used in PD patients who experience motor fluctuations not adequately controlled by oral dopaminergic medications. Pharmacokinetic studies demonstrate more consistent plasma levodopa concentrations with direct intestinal levodopa administration compared with oral formulations. 5, 6 Previous long-term LCIG safety and efficacy studies were limited by retrospective [7] [8] [9] or registry 10,11 study design and small data sets. [12] [13] [14] Recently, larger randomized, controlled, and open-label prospective studies demonstrated the safety and efficacy of LCIG treatment through 1 year, [15] [16] [17] and safety was demonstrated for an average of 2 years in an open-label extension study. 18 LCIG treatment has consistently demonstrated significant reductions in "off" time and improvements in "on" time without increasing troublesome dyskinesia.
15-17 We report our findings on patients previously enrolled in phase 3 LCIG studies 15-17 who were allowed continued access to LCIG treatment through this openlabel study until treatment became commercially available in each patient's home country. This is the longest prospective multinational study that presents LCIG safety and efficacy for advanced PD patients, with a mean follow-up of 4.1 years.
Methods Study Design and Treatment
Advanced PD patients with motor fluctuations not adequately controlled by oral dopaminergic medications who completed either a 12-week double-blind study 16 (NCT00660387/NCT0357994) and its 52-week open-label extension 17 (NCT00360568) or a separate 54-week open-label study 15 (NCT00335153)  were eligible for enrollment in this ongoing phase 3 open-label, multinational study (NCT00660673). Enrollment began in November 2009 and was completed in October 2012. Patients could remain in the study until they were transitioned to a locally available commercial product. Patients were enrolled from Australia, Canada, the Czech Republic, Israel, New Zealand, Poland, Portugal, the Russian Federation, Thailand, the United Kingdom, and the United States. Patients were excluded if they had any medical, laboratory, psychiatric, or surgical issues deemed by the investigator to be clinically significant and that could interfere with a patient's participation in the study.
LCIG was continuously administered through PEG-J (composed of separate PEG and J tubes) tubing directly into the jejunum via a portable pump for 16 hours/day. Patients' initial LCIG dose was the same as that received at the end of their previous open-label LCIG study. Dose adjustments were made by the investigator as clinically indicated. In addition to a morning dose (to prime the intestinal tube and rapidly achieve the therapeutic dose) and continuous infusion, patients could self-administer additional LCIG doses to address immediate subjective needs (eg, motor function deterioration). Patients could use oral levodopacarbidopa only for scheduled or supplemental bedtime/overnight doses after the pump was disconnected for the night.
This study was conducted in accordance with the Good Clinical Practice guideline as defined by the International Council on Harmonization, the Declaration of Helsinki, and all applicable federal and local regulations and institutional review boards.
Assessments

Safety Assessment
Patients had scheduled study visits every 6 months. Patients transitioning to a commercial product had a final study visit. Patients discontinuing LCIG had their PEG-J removed and final follow-up 1 week later. At each study visit, safety was assessed via physical examinations that included stoma-site inspection, neurological examinations, vital sign and weight measurements, and excessive daytime sleepiness assessments. Laboratory tests to evaluate selective B vitamin deficiencies were added in Protocol Amendment 2 (July 2011); because some patients were already enrolled at that time, not all had vitamin levels assessed.
Impulsive behavior was assessed using the Minnesota Impulsive Disorders Interview (MIDI). Annually, the PEG-J was evaluated by a gastroenterologist. An electrocardiogram and clinical laboratory tests were performed at the final study visit. Use of vitamin supplementation was made at the investigator's discretion, regardless of laboratory values. Adverse events (AEs) and product complaints could be reported at any time during the study.
Efficacy Assessment
Protocol amendment 4 (December 2013) for the extension study added efficacy assessments that had been used in the qualifying studies for patients at US sites: the PD symptom diary 19, 20 (PD diary), Unified Parkinson's Disease Rating Scale (UPDRS), and the Parkinson's Disease Questionnaire-39 (PDQ-39).
Statistical Analysis
Patients who received at least 1 infusion of LCIG in the current study were included in the safety population. The subset of patients who were enrolled in the United States and had at least 1 efficacy assessment in the current study were included in the efficacy population. The last assessment in the previous LCIG study served as baseline for the current study. The change in efficacy measures from baseline in the current study and from the time of each patient's initial LCIG infusion in a previous study was evaluated.
AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA, version 14.0). AEs could be coded to more than 1 preferred term. For example, AEs coded to "complication of device insertion" could also be coded other terms descriptive of the event (eg, "abdominal pain," "duodenal ulcer," "abdominal discomfort," or "bezoar"). This article includes only new AEs reported in this long-term open-label study. Standardized search strategies based on MedDRA preferred terms identified AEs of special interest in the following categories: weight loss, polyneuropathy, and procedure-/device-associated events. The polyneuropathy-related search included preferred terms in either the peripheral neuropathy or GuillainBarre syndrome standardized MedDRA query (narrow search), such as polyneuropathy, decreased vibratory sense, peripheral neuropathy, peripheral sensory neuropathy, neuralgia, demyelinating polyneuropathy, and sensory disturbance.
Efficacy variables based on the PD diary included "off" time, "on" time without troublesome dyskinesia (includes time without dyskinesia as well as time with nontroublesome dyskinesia), and "on" time with troublesome dyskinesia. PD diary times were normalized to a 16-hour waking day and averaged for the 3 days prior to each study visit. A 1-sample paired t test assessed significance in change of efficacy measures. Data are presented through the September 30, 2015, cutoff date.
Results
Patients
A total of 262 patients from 11 countries participated in this study and contributed data for the safety data set (Fig. 1 ). Most patients were male (62%), and 43% were from the United States (Table 1) . Only patients from the United States (n 5 86) were included in the efficacy subset. These patients had baseline characteristics similar to those of the overall safety population. As of the cutoff date, 110 patients (42%) had completed the study and were transitioned to commercially available LCIG; 89 (34%) had prematurely discontinued LCIG for any reason, including 
, lack of efficacy (3%), withdrawn consent (6%), administrative reasons (<1%), and protocol violations (<1%). As of the cutoff date, 63 patients (24%) were still participating in the study because they lived in countries where LCIG was not yet commercially available. The mean total exposure to LCIG in this extension study and the previous study was 4.1 years (median, 4.3 years; range, 1.2 to 6.9 years). A total of 196 patients (75%) were exposed for at least 2 years in this study (plus 1 year in the preceding studies); overall treatment with LCIG was 1081 patient-years, with 800 patientyears in this extension study. The average overall discontinuation rate was 10%/year. For the efficacy population, the mean 6 standard deviation (SD) total daily dose of levodopa was 1588 6 651 mg at study baseline (n 5 71) and 1783 6 768 mg at study end. During the study, most patients (ranging from 86% in year 1 to 92% in year 5) were on levodopa-carbidopa monotherapy (LCIG and oral levodopa-carbidopa), with half (ranging from 47% to 53%) not taking any other PD medications in addition to LCIG (Supplemental Table  1 ). At data cutoff, 30 of 71 patients used an extra LCIG dose (average of 141 mg/day).
Safety
Adverse Events
Most patients (94%) had an AE during the study; the most frequently reported AEs are shown in Table 2 . Events reported as "postoperative" as well as the term "complication of device insertion" were not always temporally linked to the procedure; "postoperative" was not defined with a specific length of time and referred to an event (eg, wound infection) that occurred any time after the procedure. The number of patients with 1 AE declined over time (year 1, 79%; year 2, 78%; year 3, 69%; year 4, 61%; year 5, 48%). Procedure-/device-related events included postoperative wound infection, excessive granulation tissue, incisionsite erythema, complication of device insertion, procedural-site reaction, abdominal pain, and Events with this term were most often also coded to "abdominal pain," "duodenal ulcer," "abdominal discomfort," or "bezoar." d Refers to the reemergence of Parkinson's symptoms, often because of a problem with drug delivery.
procedural pain; the prevalence of these events decreased over time (Fig. 2a) . Half the safety population (53%) experienced a serious AE; the most common serious AEs are shown in Table 2 . Patients experienced minimal changes in orthostatic blood pressure during the study (mean 6 SD change from baseline: systolic, 0.2 6 17.9 mm Hg; diastolic, -0.2 6 13.4 mm Hg).
Discontinuations Due to Adverse Events
AEs led to discontinuations in 62 patients (24%), including 38 deaths (15%). Of AEs leading to discontinuation, 14 patients (5%) discontinued because of a procedure-/device-related AE. The most common AEs leading to discontinuation were complications of device insertion (n 5 
Weight Loss
The mean 6 SD change from baseline in weight was a loss of 3.96 6 6.68 kg (range, a loss of 30.7 kg to a gain of 12.3 kg). Fewer than half of patients (48.4%) experienced weight loss greater than 7%. Weight loss was reported as an AE at the investigator's discretion. Weight loss-related AE terms including weight decreased, dysphagia, decreased appetite, hypophagia, and malnutrition were reported in 47 patients (18%); 36 patients (14%) reporting weight decreased. Weight loss was considered serious in 10 patients (3.8%) -weight decreased in 8 patients, and 1 patient each had dysphagia and malnutrition); only 1 case (of dysphagia) led to discontinuation.
Polyneuropathy
Polyneuropathy-related symptoms were reported in 22 patients (8%). One polyneuropathy event was considered serious. No polyneuropathy-related events led to study discontinuation. During the current study, polyneuropathy-related AE rates were relatively constant (year 1, 2.3%; year 2, 3.0%; year 3, 3.0%; year 4, 1.9%; year 5, 1.2%).
Mean laboratory values for vitamin B 6 , vitamin B 12 , folic acid, and methylmalonic acid were in normal ranges for all patients with recorded laboratory values; mean homocysteine levels were higher than the normal range (Table 3) . Of the 22 patients who experienced polyneuropathy-related AEs, mean laboratory values were in the normal ranges, except for homocysteine. The percentage of patients with polyneuropathy who had laboratory values above or below the normal ranges was similar to rates seen in the overall population. Nineteen of 22 patients with polyneuropathyrelated events were on vitamin supplementation. Of the 22 patients who experienced a polyneuropathy AE, only 1 patient experienced such an AE in the previous LCIG study. This patient reported polyneuropathy and sensory disturbance on day 309 after LCIG initiation; vitamin levels were not collected at that time.
Impulsive and Compulsive Behaviors
The number and percentage of patients reported to have specific impulse control behaviors based on the MIDI at study baseline and study end point were: pathological gambling, 1 (0.4%) and 1 (0.4%), respectively; compulsive buying, 1 (0.4%) and 2 (0.8%), respectively; and compulsive sexual behavior 1 (0.4%) and 13 (5.1%), respectively.
Device Complaints and Tube Replacements
Device complaints (ie, related to pump and tube complaints, but not necessarily associated with an AE) occurred in 244 patients (93%); the most common device complaints included device malfunction (85%), device occlusion (57%), and device dislocation (56%). Of note, device malfunction could be double-coded to other complaints, including device occlusion and device dislocation. The number of patients with device complaints associated with AEs generally decreased over time (Fig. 2b) . Of the 244 patients with device complaints, 80% had their pump replaced. The number of patients with 1 device complaint generally decreased over time (Supplemental Fig. 1) . Overall, 167 patients (63.7%) had 1 device complaint that resulted in either PEG or J tube replacement (average, 29.3% per year; range, 25.3% to 32.7%).
More than half of patients (n 5 146 [56%]) did not require PEG tube replacement; 86 (33%) had 1 PEG tube replacement, and 30 (11%) had >1 PEG tube replacement (Supplemental Fig. 2a) . Approximately one-third of the patients (n 5 88 [34%]) did not require J tube replacement, 69 (26%) had 1 J tube replacement, and 105 (40%) had >1 J tube replacement. The average 6 SD PEG tube duration was 790.2 6 438.1 days (range, 55 to 1941 days); the average 6 SD J tube duration was 575.2 6 399.1 days (range, 55 to 1941 days). PEG and J tube replacements occurred at a relatively constant rate during this multiyear study (Supplemental Fig. 2b) . The average annual rate of PEG and J tube replacements was 15.7% and 30.2%, respectively.
Deaths
There were 38 deaths (15%), of which 2 (from intestinal dilatation and cardiac arrest) were considered by the investigator to be possibly related to treatment (described in detail previously 18 ). The remaining 36 deaths were deemed unrelated to treatment and were mostly caused by complications of disease progression and advancing age.
Efficacy
Patients in the efficacy cohort (US patients only) experienced a significant decrease of nearly 4 hours in mean daily hours of "off" time from prior to initial LCIG infusion (in a previous study) to study end point (P < 0.001), with no significant change from study baseline to end point (Supplemental Fig. 3a) . Patients also experienced a significant increase of approximately 4 hours in mean daily hours of "on" time without troublesome dyskinesia (P < 0.001; Supplemental Fig. 3b ) that was maintained. Patients' mean daily "on" time with troublesome dyskinesia was significantly lower (decrease of 0.6 hours) from prior to initial LCIG infusion to study baseline (P < 0.05; Supplemental Fig. 3c) ; however, this reduction was not maintained during the extension study.
UPDRS total score, as well as part II (activities of daily living) and part III (motor) scores, demonstrated significant improvements (mean score improvement of 3.03 and 4.77, respectively) from prior to initial LCIG infusion to study baseline; however, this improvement was not maintained over the course of this study (Supplemental Table 2 ). Similarly, PDQ-39 summary index score demonstrated a mean improvement of 8.1 from prior to initial LCIG infusion to study baseline; this improvement was not maintained over the course of this study.
Discussion
This study includes follow-up of patients who initiated LCIG treatment in a previous randomized, Study baseline is entry into this extension study (ie, after 52 to 74 weeks of LCIG treatment in a previous study). b Patients could fall into both categories at any given time during the study; columns do not add up to 100%. Includes patients who experienced decreased vibratory sense, demyelinating polyneuropathy, neuralgia, peripheral neuropathy, peripheral sensory neuropathy, polyneuropathy, and sensory disturbance.
controlled trial and an open-label trial. Thus, our findings are limited by differences in study design and selection bias of the original studies from which patients were recruited. Patients were recruited from specialized movement disorders centers and therefore may be managed differently than patients in typical hospital settings. Efficacy was only assessed in a subset of the population, and the study was not powered for analysis in this smaller population subset. Further, although some patients began LCIG in a double-blind study, most of the patients began LCIG in an openlabel study. Combining patients from these studies may overestimate the true benefit of LCIG beyond that reported in the parent studies. The study-required AE reporting may be artificially inflated; however, patient monitoring in this study is closer to clinical practice than the preceding studies, with visits every 6 months and limited study-specific assessments. Despite these limitations, this is the longest prospective study to date evaluating the safety and efficacy of LCIG, with an average infusion of 4.1 years. Although a high incidence of AEs was noted, long-term use was associated with a relatively low 21 annual discontinuation rate (average, 10% per year), with overall discontinuation rates similar to other long-term follow-up studies 8-10,13,21-28 and low incidence of serious AEs.
Frequently reported AEs were associated with PEG-J complications (mainly related to stoma-site maintenance), comorbidities associated with advanced PD (eg, fall, fracture), aging (eg, fractures, osteoarthritis), or dopaminergic therapy (eg, dyskinesia, insomnia). The overall safety profile was like that reported in a recent integrated summary of safety of an average LCIG exposure of just more than 2 years, 18 as well as prospective open-label 10, 11, 13, [25] [26] [27] [28] [29] and retrospective observational studies. [7] [8] [9] 14, 22, 23 A total of 36 patients (14%) reported AEs related to weight loss, as was also reported in the integrated safety study (59 patients [14%]) 18 and was similar to rates reported in a retrospective survey of more than 900 patients 23 and a prospective open-label routine-care study of 59 patients. 11 Although impulse control disorders are common in PD patients and were an exclusion to enrollment, the treatment-emergent rate in this study was low, with an increase in compulsive sexual behavior from study baseline to the end of the study from 0.4% to 5.1%. Increased rates of impulse control disorders are not uncommon-a study assessing longterm rotigotine treatment identified a frequency of impulse control disorders of 0.6% after 6 months that increased to 9% after 6.5 years. 30 Nonambulatory patients with enteral tubes for nutrition have experienced an average J-tube longevity of 3 to 6 months. 31 PD patients treated with LCIG are mobile, and issues related to enteral tube longevity (eg, tube displacement), would be expected. However, PEG and J tubes were durable during LCIG treatment, with an average PEG and J-tube duration of 2.2 and 1.6 years, respectively. The average tube longevity in this study was greater than the average longevity of 12 months reported in a retrospective survey 23 and was like the 2.4-year average longevity reported in an observational study. 24 Generally, PEG and J tubes are replaced when needed; however, it is unknown how many tubes were replaced preventively, as a cosmetic measure (eg, deterioration in the tube appearance), or whether the PEG and J components were replaced independently. In addition, J tubes require replacement when PEG tubes are replaced. PEG and J tubes were each replaced a median 1 time in the study; patients with an unusual number of tube replacements (ie, more than 5) generally had unique circumstances. For example, 1 patient with 12 J-tube replacements had dementia and frequently pulled the tube out during confusional states. Other studies have cited dementia (which results in accidental removal of tubes) as a reason for discontinuation 28 and is a point of consideration when deciding if a patient should continue LCIG treatment. Patients who had device complaints commonly had their pump replaced to correct situations such as error codes.
The polyneuropathy rate in this population (3.4%) is similar to what has been reported in observational studies of patients treated with LCIG (rates of 3%, reported in 2 studies, 10,29 5.4%, 27 and 7%
11
). Polyneuropathy rates were similar in the previous study (first year of treatment), with 18 patients (4.4%) experiencing polyneuropathy. 15 Similarly, 33 patients (8.0%) experienced polyneuropathy-related events in the first year of treatment (previous study), 15 and 22 (8%) reported polyneuropathy-related symptoms in the current study, thus indicating a relatively constant rate of polyneuropathy and polyneuropathy-related events. These rates are much lower than the polyneuropathy rates of 14%, 13 19%, 32 and 35% 25 reported in other prospective open-label studies. Despite reports that polyneuropathy with levodopa treatment may be associated with hyperhomocysteinemia and low levels of vitamin B 6 , vitamin B 12 , folic acid, and methylmalonic acid, 33 patients experiencing polyneuropathyrelated AEs in this study had mean laboratory values for these vitamins (except homocysteine) that were in normal ranges. However, most patients experiencing polyneuropathy-related AEs were on vitamin supplementation. In addition, vitamin levels were not assessed after fasting. As a result, causality between LCIG, vitamin deficiencies, and polyneuropathy cannot be established. Monitoring these vitamin levels was included as a protocol amendment; thus, baseline vitamin levels (before initial LCIG treatment in previous studies) were not available for most patients. Further systematic surveillance of vitamin levels is warranted to determine if vitamin supplementation may be considered in these patients.
Motor improvement from LCIG treatment was sustained and clinically meaningful, as demonstrated by decreased "off" time and increased "on" time without troublesome dyskinesia. Although these motor improvements were not supported by the UPDRS part II scores and PDQ-39 summary index and subdomain scores, there was no motor worsening, as indicated by negligible change in the "on" state UPDRS part III scores. As mentioned earlier, the methodological limitations of this study restrict the conclusions that can be made from the efficacy data. A long-term prospective (ideally double-blind) study is needed to further assess long-term efficacy in patients receiving LCIG. Diminished improvement over time in PDQ-39 scores has been reported in long-term follow-up of patients treated with deep brain stimulation, which may reflect disease progression, treatment-related AEs (such as speech deterioration 34 ), related comorbidities, or emergence of treatment-resistant symptoms. 35 Because of general disease progression, advanced PD patients typically experience increases in UPDRS part II scores. Levodopa-treated patients have experienced PD progression in the form of an increase of 1.72 points/year in UPDRS part II 36 (compared with an increase of 4.4 points/year in untreated patients 37 ). In the current study, patients experienced an approximate rate of increase of 1.5 points/year. These results are similar to other long-term open-label studies, which reported slight increases in UPDRS part II scores after 24 months of treatment 27 and no change in UPDRS part II scores after 4 years. 10 A retrospective study that compared outcomes in patients receiving LCIG, deep brain stimulation, or optimized standard oral therapy found that after an average of 5 years of treatment, the magnitude of worsening of UPDRS part II scores was similar between patients receiving LCIG and deep brain stimulation and was lower for those patients receiving optimized oral therapy, indicating that LCIG and deep brain stimulation ameliorated the deterioration of activities of daily living that occurs in patients treated with optimized oral medication. 14 In the initial 64 weeks of LCIG treatment in previous studies, the most common AEs were related to the procedure 15, 16 ; however, with long-term use, patients experienced fewer of these complications. Most patients were on levodopa monotherapy, and levodopa dose was constant/slightly increased over time, suggesting long-term tolerability of the dose needed to control motor symptoms/fluctuations. No correlation was noted between peripheral neuropathy and vitamin B levels, other than high homocysteine. Despite sustained motor improvements provided by LCIG, several comorbidities and complications, including death, do occur. Device-related complications were common and required vigilance, although they were generally reversible and seldom led to discontinuation. AEs were typical of the known risks of the PEG-J system, the advanced disease state, or the patient population. Therefore, despite the seemingly high rate of AEs, our long-term study suggested an overall favorable benefit/ risk profile for long-term LCIG treatment. 
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